Inamed Finalizing Lap-Band Treatment IDE Plans, Collecting Three-Year Data
This article was originally published in The Gray Sheet
Executive Summary
Inamed is expecting to hear from FDA within the next few weeks about expanding its Lap-Band obesity treatment training program under a treatment investigational device exemption, President and co-CEO Ilan Reich told a July 25 teleconference announcing second-quarter financial results.